Patent ID: 9328103
Filing Date: 2016-05-03
CPC Classification: A61P,C07D

Claim Text:
1. A method of treating a disease or condition in a human subject, wherein said disease or condition is selected from the group consisting of colorectal cancer, lung cancer, hematological cancer, renal cancer, liver cancer, breast cancer, ocular angiogenesis, retinal edema, retinal ischemia, diabetic macular edema, cystoid macular edema, retinal vein occlusion, branch vein occlusion, preretinal neovascularization, laser-induced choroidal neovascularization, neovascularization associated with keratoplasty, glaucoma and ocular tumors, arthritis, restenosis, hepatic cirrhosis, atherosclerosis, psoriasis, diabetes mellitus, wound healing, inflammation, neurodegenerative diseases and immune disorders, comprising administering to said human subject a therapeutically effective amount of at least one compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein: X is selected from the group consisting of NR n is 0 or an integer of from 1 to 2; R R a is 0 or an integer of from 1 to 3; d is 0 or an integer of from 1 to 5; e is an integer of from 1 to 4; f is 0 or an integer of from 1 to 2; R b is 0 or an integer of from 1 to 2; Y is selected from the group consisting of: wherein g is 0 or an integer of from 1 to 3; h is 0 or an integer of from 1 to 3; R R Ring A in the structure is selected from the group consisting of: (i) Phenyl; and (ii) Naphthyl; R III represents optionally 1-3 substituents independently selected from the group consisting of C 1 -C 5 linear or branched alkyl, C 1 -C 5 linear or branched haloalkyl, C 1 -C 5 alkoxy, hydroxy, amino, C 1 -C 5 alkylamino, C 1 -C 6 dialkylamino, halogen, cyano, and nitro; Z is selected from the group consisting of (1′) (CH (2′) (CH (3′) (CH (4′) C(O)N(R (5′) (CH and (6′) S(O) wherein: Ring B in the structure is selected from the group consisting of: (i′) Phenyl; and (ii′) Naphthyl; and R IV represents optionally 1-3 substituents, independently selected from the group consisting of alkoxy, alkoxyalkyl, alkoxycarbonyl, alkyl, aryloxy, arylalkyl, carboxy, cyano, halo, haloalkoxy, haloalkyl, hydroxy, hydroxyalkyl, nitro, and —NR 9 R 10 ; wherein R 9 and R 10 are independently selected from the group consisting of hydrogen, alkyl, alkylcarbonyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, and heterocyclylalkyl.